How to buy Sierra Oncology stock | $15.12

Sierra Oncology, Inc is a biotechnology business based in the US. Sierra Oncology shares (SRRA) are listed on the NASDAQ and all prices are listed in US Dollars. Sierra Oncology employs 71 staff and has a trailing 12-month revenue of around USD$100,000.

How to buy shares in Sierra Oncology

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Sierra Oncology. Find the stock by name or ticker symbol: SRRA. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Sierra Oncology reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$15.12, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Sierra Oncology, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Sierra Oncology. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Sierra Oncology share price

Use our graph to track the performance of SRRA stocks over time.

Sierra Oncology shares at a glance

• Key figures

Information last updated 2020-11-30.

Latest market close	USD$15.12
52-week range	USD$8.545 - USD$22
50-day moving average	USD$13.611
200-day moving average	USD$12.6543
Wall St. target price	USD$25
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-0.775

Buy Sierra Oncology shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Sierra Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Sierra Oncology, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Sierra Oncology price performance over time

Historical closes compared with the close of $15.12 from 2020-12-09

1 week (2021-01-07)	-5.03%
1 month (2020-12-15)	0.47%
3 months (2020-10-15)	24.55%
6 months (2020-07-15)	25.90%

1 year (2020-01-15)	3,336.36%
2 years (2019-01-15)	1,011.76%
3 years (2018-01-13)	N/A
5 years (2016-01-15)	53.81%

Sierra Oncology financials

Revenue TTM	USD$100,000
Gross profit TTM	USD$0
Return on assets TTM	-46.43%
Return on equity TTM	-134.39%
Profit margin	0%
Book value	$10.038
Market capitalisation	USD$156.2 million

TTM: trailing 12 months

Shorting Sierra Oncology shares

There are currently 13,639 Sierra Oncology shares held short by investors – that's known as Sierra Oncology's "short interest". This figure is 8.5% up from 12,574 last month.

There are a few different ways that this level of interest in shorting Sierra Oncology shares can be evaluated.

Sierra Oncology's "short interest ratio" (SIR)

Sierra Oncology's "short interest ratio" (SIR) is the quantity of Sierra Oncology shares currently shorted divided by the average quantity of Sierra Oncology shares traded daily (recently around 13776.767676768). Sierra Oncology's SIR currently stands at 0.99. In other words for every 100,000 Sierra Oncology shares traded daily on the market, roughly 990 shares are currently held short.

However Sierra Oncology's short interest can also be evaluated against the total number of Sierra Oncology shares, or, against the total number of tradable Sierra Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sierra Oncology's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Sierra Oncology shares in existence, roughly 0 shares are currently held short) or 0.0036% of the tradable shares (for every 100,000 tradable Sierra Oncology shares, roughly 4 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sierra Oncology.

Find out more about how you can short Sierra Oncology stock.

Sierra Oncology share dividends

We're not expecting Sierra Oncology to pay a dividend over the next 12 months.

Have Sierra Oncology's shares ever split?

Sierra Oncology's shares were split on a 1:40 basis on 23 January 2020. So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sierra Oncology shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for Sierra Oncology shares which in turn could have impacted Sierra Oncology's share price.

Sierra Oncology share price volatility

Over the last 12 months, Sierra Oncology's shares have ranged in value from as little as $8.545 up to $22. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sierra Oncology's is 1.3709. This would suggest that Sierra Oncology's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Sierra Oncology overview

Sierra Oncology, Inc. researches, develops, and commercializes therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has been investigated in two completed Phase 3 trials for the treatment of myelofibrosis. The company is also advancing SRA737, an orally bioavailable small molecule inhibitor Checkpoint kinase 1 is being investigated in two Phase 1/2 clinical trials; and SRA141, an orally bioavailable small molecule inhibitor of cell division cycle 7 kinase. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Frequently asked questions

• What percentage of Sierra Oncology is owned by insiders or institutions?

  Currently 3.273% of Sierra Oncology shares are held by insiders and 80.836% by institutions.

• How many people work for Sierra Oncology?

  Latest data suggests 71 work at Sierra Oncology.

• When does the fiscal year end for Sierra Oncology?

  Sierra Oncology's fiscal year ends in December.

• Where is Sierra Oncology based?

  Sierra Oncology's address is: 885 West Georgia Street, Vancouver, BC, Canada, V6C 3E8

• What is Sierra Oncology's ISIN number?

  Sierra Oncology's international securities identification number is: US82640U4040

• What is Sierra Oncology's CUSIP number?

  Sierra Oncology's Committee on Uniform Securities Identification Procedures number is: 74346L101